Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
51 hedge funds and large institutions have $7.99M invested in Pear Therapeutics, Inc. Warrant in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
13% more funds holding
Funds holding: 45 → 51 (+6)
8% less capital invested
Capital invested by funds: $8.7M → $7.99M (-$708K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$347K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$299K |
| 3 |
SRF
Silver Rock Financial
Los Angeles,
California
|
+$220K |
| 4 |
AGM
Alpine Global Management
New York
|
+$174K |
| 5 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$87.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
-$237K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$165K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$70K |
| 4 |
CAC
Cowen and Company
New York
|
-$22K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.67K |
PEARW Hedge Fund Activity: Q3 2021 in Review
51 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q3 2021, worth a combined $7.99M — down 8.1% from $8.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PEARW positions and 3 closed out — a net gain of 6 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was BlueCrest Capital Management, opening a new position worth an estimated $347K. The largest seller was Linden Advisors, exiting entirely with an estimated $237K sold.
- 51 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q3 2021, up from 45 in Q2 2021.
- Funds reported $7.99M of Pear Therapeutics, Inc. Warrant stock for Q3 2021, down 8.1% quarter-over-quarter.
- 9 funds opened new Pear Therapeutics, Inc. Warrant positions in Q3 2021 and 3 closed out, a net change of +6 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q3 2021 was BlueCrest Capital Management, an estimated $347K added.
- The largest Pear Therapeutics, Inc. Warrant seller in Q3 2021 was Linden Advisors, an estimated $237K sold.
Based on aggregated 13F filings for Q3 2021.